Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12340 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 2612 trials in this tab.
-
Could a Half-Matched donor cure a rare immune disease?
⭐️ CURE ⭐️ OngoingThis early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…
Phase: EARLY_PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 01:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing an experimental cell therapy for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to recognize …
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a Patient's own immune cells be trained to cure leukemia?
⭐️ CURE ⭐️ OngoingThis trial tests a personalized therapy where a patient's own T cells are collected, genetically modified to recognize and attack CD19-positive leukemia cells, and then infused back into the patient. It is designed for children and young adults with relapsed or refractory CD19+ a…
Phase: PHASE1, PHASE2 • Sponsor: Seattle Children's Hospital • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
⭐️ CURE ⭐️ OngoingThis trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
Can reprogrammed immune cells silence lupus? a small trial aims to find out.
⭐️ CURE ⭐️ ENROLLING_BY_INVITATIONThis trial tests whether anti-CD19 CAR-T cell therapy can put severe lupus into remission. The treatment involves taking a patient's own immune cells, engineering them to target and destroy faulty B cells, and infusing them back. The study enrolls 12 adults with refractory system…
Sponsor: N.N. Alexandrov National Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
A One-Shot gene therapy could take on incurable blood cancer
⭐️ CURE ⭐️ TerminatedThis early-phase trial is testing a new gene therapy called ESO-T01 for people with relapsed or refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. ESO-T01 is given as an injection and works by instructing the body's own cells to become…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Can a second CAR T-Cell infusion beat lymphoma that returns?
⭐️ CURE ⭐️ TerminatedThis early-stage trial is testing whether a second infusion of a patient's own genetically modified immune cells (CAR T-cells) can safely treat B-cell lymphoma that has returned after an initial successful response. The study enrolls people with diffuse large B-cell or follicular…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged immune cells take aim at cancer and viruses in one shot
⭐️ CURE ⭐️ OngoingThis study tests a new type of immune cell therapy for people with CD19-positive leukemia or lymphoma who have had a stem cell transplant. The cells are specially designed to both recognize and kill cancer cells (through a CD19-targeting antibody) and fight three common viruses (…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: ⭐️ CURE ⭐️
Last updated Jul 16, 2026 00:00 UTC
-
Can the HPV vaccine protect those with a weak immune system?
⭐️ VACCINE ⭐️ OngoingThis study tests whether the HPV vaccine Gardasil 9 can trigger an immune response in people with idiopathic CD4 T cell lymphocytopenia (ICL), a rare condition that weakens the immune system. About 54 adults with ICL and some healthy volunteers will receive three doses of the vac…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 18, 2026 01:00 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control TerminatedThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Can a healthy diet prolong the 'Honeymoon Phase' in kids with type 1 diabetes?
Disease control OngoingThis pilot study is testing whether giving children (ages 6-17) newly diagnosed with stage 3 type 1 diabetes free weekly healthy foods and intensive nutrition counseling can help preserve their remaining insulin production. The study will enroll 20 children and measure how feasib…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New knee implant tested for better mobility and less pain
Disease control ENROLLING_BY_INVITATIONThis study is testing a new knee implant called the Persona SoluTion PPS femur in 200 adults who need total knee replacement. The goal is to see if it safely improves knee function and reduces pain over two years. Participants will have their knee health measured before surgery a…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Immunotherapy drug avelumab takes on rare thymus cancers
Disease control OngoingThis phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Cheaper MS drug could match pricey standard in major trial
Disease control OngoingThis phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…
Phase: PHASE3 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New cocktail targets Hard-to-Treat myeloma
Disease control OngoingThis early-stage trial is testing the safety of adding venetoclax to standard multiple myeloma treatments for people whose cancer cells have a specific genetic change called t(11;14). The study will enroll 100 participants and try different drug combinations to find the best dose…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New hope for tough lymphoma: experimental drug CHO-H01 enters human trials
Disease control OngoingThis study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New pill could tame stubborn ulcerative colitis
Disease control OngoingThis study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. Participants take either the drug or a placebo for 12 weeks, then everyone gets the drug for up to a year. The goal is to see if TAK-279 reduces bowel inflammation…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New knee implant under review: could it ease arthritis pain?
Disease control OngoingThis study is testing the Persona Ti-Nidium knee implant in 240 people who need total knee replacement due to conditions like osteoarthritis or rheumatoid arthritis. The goal is to see if the implant is safe and improves knee function and pain. Participants will be followed over …
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New MS drug tolebrutinib tested for Long-Term safety in 2,500 patients
Disease control OngoingThis study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New cocktail of cancer drugs shows promise in early lymphoma trial
Disease control OngoingThis early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About …
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New stem cell approach aims to cure rare immune disease
Disease control OngoingThis study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New combo therapy aims to deepen remission in multiple myeloma
Disease control OngoingThis phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New split-dose chemo aims to help elderly lymphoma patients
Disease control OngoingThis study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven p…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New biologic mirikizumab put to the test against standard therapies for IBD
Disease control ENROLLING_BY_INVITATIONThis study compares the real-world effectiveness of mirikizumab against standard biologic therapies for adults with ulcerative colitis or Crohn's disease. Researchers will track whether mirikizumab reduces the need for extra medical care, like emergency visits or treatment change…
Phase: PHASE4 • Sponsor: Specialty Networks Research. • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control TerminatedThis study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New antibody combo shows promise for Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New lupus drug afimetoran enters Mid-Stage trial
Disease control OngoingThis phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase: PHASE2 • Sponsor: Beeline Medicines Corporation • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
Experimental cocktail targets Hard-to-Treat brain cancer
Disease control OngoingThis early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 01:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene fix trial aims to tame rare immune disease
Disease control ENROLLING_BY_INVITATIONThis study tests a gene therapy for people with X-linked chronic granulomatous disease (X-CGD), a genetic condition that weakens the immune system and leads to severe infections. Researchers take the patient's own stem cells, add a working copy of the faulty gene, and return the …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can immune cells plus a checkpoint drug outsmart lymphoma?
Disease control OngoingThis early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eczema drug shows promise in long-term real-world study
Disease control OngoingThis study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New stem cell therapy aims to tame transplant complications
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with rare muscle disease: rozanolixizumab safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control OngoingThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take aim at myasthenia gravis
Disease control OngoingThis Phase 2 trial is testing an experimental therapy called Descartes-08 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Descartes-08 uses a patient's own immune cells, engineered to target and potentially reduce the harmful immune cells t…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug keep Crohn's disease in check?
Disease control OngoingThis clinical trial is testing whether risankizumab, an experimental drug, can safely and effectively maintain remission in people with moderate to severe Crohn's disease who have already responded to initial treatment. Participants will receive either risankizumab or a placebo f…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat myeloma
Disease control OngoingThis early-stage study tests a new drug called etentamig combined with standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 320 adults will take part to find the safest dose and check for side effects. The goal is to cont…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Poop pills may tame severe immunotherapy side effects in cancer patients
Disease control TerminatedThis study tests a treatment made from healthy donor stool (MTP-101-C) for cancer patients whose skin or gut side effects from immunotherapy don't get better with steroids. About 30 participants will take the oral capsules to see if the therapy is safe and can calm these side eff…
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma? early trial of ABBV-291 begins
Disease control OngoingThis early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of back pain condition
Disease control OngoingThis study is testing the long-term safety and effectiveness of bimekizumab, a drug that reduces inflammation, in 508 adults with active axial spondyloarthritis (including ankylosing spondylitis). Participants who completed earlier trials will receive the drug for an extended per…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot for eczema shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug hope for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…
Phase: PHASE2, PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Weekly shot may help short kids grow – new study underway
Disease control OngoingThis study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for blood disorder patients: experimental drug bomedemstat enters final trial phase
Disease control OngoingThis study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (a blood disorder causing too many platelets) who did not respond well to or couldn't tolerate the standard drug hydroxyurea. About 340 adults will be ra…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
Disease control TerminatedThis study tests whether giving the drug anakinra early can prevent severe cytokine release syndrome (CRS) in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who are receiving CAR-T cell therapy. Participants receive anakinra at the first sign of fever,…
Phase: PHASE1, PHASE2 • Sponsor: Kevin McNerney • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New MS pill aims to slow disability in phase 3 showdown
Disease control OngoingThis study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MS drug ocrelizumab gets a Needle-Free makeover: new shot form tested
Disease control OngoingThis early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Phase: PHASE2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental cocktail aims to outsmart resistant myeloma
Disease control OngoingThis early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up…
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Dual-Action pill tame bone marrow tumors?
Disease control TerminatedThis phase 1 trial is testing an experimental pill called flonoltinib maleate in people with certain bone marrow tumors, including myelofibrosis, polycythemia vera, and essential thrombocythemia. The drug targets two proteins involved in abnormal blood cell growth. The study aims…
Phase: PHASE1 • Sponsor: Guizhou Bailing Group Pharmaceutical Co Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cocktail aims to deeply suppress bone marrow cancer
Disease control OngoingThis study tests a combination of four drugs—daratumumab, carfilzomib, lenalidomide, and dexamethasone—in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or stringent complete response after initial treatmen…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo shot aims to tame type 1 diabetes
Disease control OngoingThis early-stage trial tests a new weekly injection called NNC0194-0499, alone or with another drug (semaglutide), in 96 adults with type 1 diabetes. The goal is to see if it improves blood sugar levels compared to placebo. All participants continue their usual insulin. The study…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug could simplify treatment for rare EGPA disease
Disease control OngoingThis study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids.…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for kids with arthritis: drug trial shows promise
Disease control OngoingThis study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control OngoingThis trial is testing an experimental drug called flonoltinib in people with intermediate to high-risk myelofibrosis, a type of bone marrow cancer that often causes an enlarged spleen. Participants will be randomly assigned to receive either a low or high dose of flonoltinib, or …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug sonelokimab aims to ease psoriatic arthritis pain
Disease control OngoingThis study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could ease daily struggles of myasthenia gravis
Disease control OngoingThis study tests an oral drug called iptacopan in people with generalized myasthenia gravis (gMG) who are already on standard treatment. About 146 adults will receive either iptacopan or a placebo for 6 months to see if it improves their ability to do daily activities and reduces…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare blood cancers? early trial begins
Disease control OngoingThis early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the right dose and…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can calming the immune system save Kids' livers?
Disease control OngoingThis study tests whether two drugs that calm the immune system—high-dose steroids or anti-thymocyte globulin—can help children with sudden, severe liver failure survive without needing a liver transplant. About 163 children aged 1 to 17 will be randomly assigned to receive one of…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental combo aims to tame aggressive lymphoma without chemo
Disease control OngoingThis early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding a targeted antibody to radiation keep lymphoma away?
Disease control OngoingThis study looks at whether adding the drug rituximab to standard radiation therapy helps people with early-stage follicular lymphoma stay cancer-free longer. About 81 patients with stage I or II low-grade lymphoma are being randomly assigned to get radiation alone or radiation p…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Which hip implant lasts longer? a Head-to-Head trial aims to find out
Disease control OngoingThis trial is testing two different cup designs for total hip replacement, both paired with the same stem, to see which one gives patients better hip function and less pain. About 120 people with hip arthritis or related conditions will be randomly assigned to receive either the …
Phase: NA • Sponsor: Limacorporate S.p.a • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gentler chemo combo shows promise for older leukemia patients
Disease control OngoingThis study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental drug targets rare thymus cancers after chemotherapy fails
Disease control OngoingThis phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study ai…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a lighter MS treatment keep the disease at bay?
Disease control OngoingThis study tests whether people with relapsing-remitting multiple sclerosis (MS) who have been stable on anti-CD20 therapies can safely switch to a fumarate drug like Tecfidera or Vumerity. The goal is to see if the switch keeps the disease inactive—meaning no relapses, no new br…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New knee implant aims to get patients moving again
Disease control OngoingThis study follows 299 people who received the Smith+Nephew Porous Total Knee System, a titanium knee replacement for severe arthritis. The goal is to see if the implant reduces pain, improves movement, and lasts at least two years without needing revision surgery. Participants a…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Triple-Drug cocktail tame resistant myeloma?
Disease control OngoingThis trial is testing whether a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—can help people with multiple myeloma that has relapsed or become resistant after prior treatments like daratumumab, lenalidomide, and bortezomib. The study will measure how long …
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for leukemia patients: drug cocktail shows promise
Disease control ENROLLING_BY_INVITATIONThis phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
A smarter steroid schedule might tame Chemotherapy's blood sugar spike
Disease control OngoingThis trial tests whether adjusting the dose of prednisone, a steroid in the R-CHOP chemotherapy regimen, can prevent high blood sugar (hyperglycemia) in adults with B-cell non-Hodgkin lymphoma. Participants are randomly assigned to either the standard prednisone dose or a tailore…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill boost Chemotherapy's punch against lymphoma?
Disease control OngoingThis trial is testing whether adding the experimental drug tazemetostat to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or high-risk follicular lymphoma. The study has two parts: first, to find…
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo tackles Hard-to-Treat myeloma
Disease control OngoingThis early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on tough childhood leukemia in new trial
Disease control OngoingThis study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for Crohn's: Long-Term drug study shows promise
Disease control OngoingThis study looks at how well and how safely the drug mirikizumab works over the long term for people with Crohn's disease. About 996 adults who were in earlier mirikizumab studies will continue treatment. The goal is to see if the drug can keep the gut healed and symptoms under c…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Promising new cocktail targets AIDS-Linked cancers
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this co…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug could make stem cell transplants safer for rare immune disorder
Disease control OngoingThis phase II trial tests whether a new drug called Briquilimab can make stem cell transplants safer for people with GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of infections and blood cancers. The study involves 13 participants a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug could free diabetics from insulin after cell transplant
Disease control OngoingThis study tests whether a lab-made antibody called Tegoprubart can safely prevent the immune system from attacking transplanted islet cells in people with type 1 diabetes who have dangerous low blood sugar. The goal is to help patients stop needing insulin without using standard…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to tame rare blood cancers
Disease control OngoingThis early-stage trial is testing a new drug called INCA033989, alone or with an existing drug ruxolitinib, in 225 people with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the best dose. Participants must have a specific genet…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Hope for rare Muscle-Weakening disease: new drug trial targets Antibody-Negative patients
Disease control OngoingThis study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to wipe out hidden leukemia cells in High-Risk patients
Disease control OngoingThis study is for people with high-risk chronic lymphocytic leukemia (CLL) who have been on ibrutinib or acalabrutinib for at least a year but still have detectable disease. Researchers want to see if adding venetoclax for 12 cycles can clear remaining leukemia cells from the bon…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis phase II trial is testing two oral drugs, venetoclax and acalabrutinib, in 32 people with mantle cell lymphoma that has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Both drugs work by blocking …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising combo targets tough leukemia
Disease control OngoingThis study tests a new way to treat adults with a specific type of leukemia (Ph+ ALL) that has come back or not responded to treatment. The approach combines low-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to kill cancer cells and boost the immune …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Gene-Targeted pill turn the tide against a rare blood cancer?
Disease control OngoingThis trial is testing an oral drug called AG-120 (ivosidenib) in adults with myelodysplastic syndrome (MDS) or a related early form of leukemia that carries a specific IDH1 gene mutation. The drug is designed to block the mutated enzyme that drives abnormal blood cell growth. Res…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a targeted pill turn the tide against a bone marrow disorder?
Disease control OngoingThis trial is testing an oral drug called enasidenib (AG-221) in people with myelodysplastic syndrome (MDS) who have a specific genetic change called an IDH2 mutation. The drug is designed to block the mutated enzyme and help restore normal blood cell production. Participants rec…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to stop leukemia from coming back after transplant
Disease control TerminatedThis early-phase trial tests a drug called DR-18 in 40 adults with acute myeloid leukemia or myelodysplastic syndrome whose cancer returned or persisted after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against cancer c…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial
Disease control OngoingThis study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to deepen remission in myeloma transplant patients
Disease control OngoingThis phase 2 trial is testing whether adding the targeted drug belantamab mafodotin before and after a stem cell transplant can help people with multiple myeloma achieve deeper remission. About 41 participants will receive the drug alongside standard treatments. The main goal is …
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Daily pill may beat weekly shot for kids with MS
Disease control OngoingThis study tests whether a daily fingolimod capsule works better than a weekly interferon injection to prevent multiple sclerosis relapses in children. About 240 kids with MS will take one of the two treatments for 2 years, followed by a 5-year extension where everyone gets fingo…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare blood cancer: zanubrutinib trial targets untreated patients
Disease control OngoingThis study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth,…
Phase: PHASE4 • Sponsor: BeiGene • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy takes on progressive MS
Disease control OngoingThis early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation…
Phase: PHASE1 • Sponsor: Bruce Cree • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a simpler dosing schedule for an MS drug work just as well?
Disease control OngoingThis study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug axatilimab tested for Hard-to-Treat Graft-Versus-Host disease in china
Disease control OngoingThis study tests a drug called axatilimab in 30 Chinese patients with chronic graft-versus-host disease (cGVHD) that has come back or not improved after standard treatment. cGVHD is a complication of bone marrow or stem cell transplants where donor cells attack the patient's body…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for blood cancer patients: experimental drug BGB-16673 enters phase 3 trial
Disease control OngoingThis Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough nerve disease: experimental drug riliprubart enters final testing
Disease control OngoingThis study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could tame tough eczema
Disease control OngoingThis study tests a new drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug improves eczema symptoms by at least 75% aft…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests two oral drugs, olutasidenib and ziftomenib, together in 20 adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds a safe dose; the second checks if that dose helps control the…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Smart drug hunts down hidden leukemia cells
Disease control OngoingThis phase II trial tests inotuzumab ozogamicin, a drug that targets and kills leukemia cells carrying a specific marker (CD22). It enrolls 40 adults with B-cell acute lymphoblastic leukemia who are in remission but still have minimal residual disease (MRD) — tiny amounts of canc…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Frozen poop pills could tame ulcerative colitis
Disease control OngoingThis study tests whether frozen capsules containing processed stool from healthy donors can help people with mild-to-moderate active ulcerative colitis. Participants will take either the real capsules or a placebo for 12 weeks. The goal is to see if the treatment can bring the di…
Phase: PHASE3 • Sponsor: Andreas Stallmach • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control ENROLLING_BY_INVITATIONThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Promising combo offers hope for elderly lymphoma patients
Disease control OngoingThis study tests a combination of two drugs, acalabrutinib and rituximab, in people aged 65 and older with newly diagnosed mantle cell lymphoma who haven't had treatment yet. Acalabrutinib blocks enzymes that help cancer grow, while rituximab targets and kills cancer cells. The g…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Promising combo targets tough leukemia in early trial
Disease control OngoingThis study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…
Phase: PHASE1, PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental CAR t therapy takes on Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial is testing a new type of CAR T cell therapy called TriPRIL for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to better attack cancer,…
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill combo aims to outsmart leukemia in major trial
Disease control OngoingThis Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for lymphoma patients: drug combo trial aims to shrink tumors
Disease control OngoingThis early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug boost the fight against an aggressive blood cancer?
Disease control OngoingThis trial is testing whether adding the targeted drug acalabrutinib to the standard CHOP-R chemotherapy regimen can improve outcomes for people newly diagnosed with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). Richter's syn…
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of IBD
Disease control OngoingThis study tests two different doses of TEV-48574 (duvakitug) given as a shot every 4 weeks to adults with moderate to severe ulcerative colitis or Crohn's disease. Participants who completed a previous 14-week study can join. The goal is to see if the drug can keep the disease u…
Phase: PHASE2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New app aims to boost HIV medication adherence in Spanish-Speaking communities
Disease control OngoingThis study tests a mobile app called WiseApp along with a smart pill dispenser to help Spanish-speaking people with HIV take their medication regularly. About 248 participants from New York City and the Dominican Republic will use the app for 12 months. The goal is to see if the …
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients
Disease control OngoingThis study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New strategy cuts early deaths in rare leukemia
Disease control OngoingThis study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can lower chemo doses help babies with SCID build better immunity?
Disease control OngoingThis phase 2 trial studies whether lower doses of the chemotherapy drug busulfan can help infants with severe combined immunodeficiency (SCID) achieve good immune function after a stem cell transplant, while reducing short- and long-term risks. The trial includes 56 babies receiv…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for rare thymic cancer
Disease control OngoingThis study tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic cancer that had spread or could not be removed and had stopped responding to standard chemotherapy. The goal was to see if the combination could shrink tumors or stop them …
Phase: PHASE2 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New lupus drug candidate enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
Disease control OngoingThis phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New Stomach-Slimming procedure tested for ulcerative colitis patients
Disease control OngoingThis study is testing a minimally invasive weight loss procedure called endoscopic sleeve gastroplasty (ESG) in 12 people who have both obesity and ulcerative colitis and are planning or have had colon removal surgery. The procedure uses a suturing device to reduce stomach size b…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New shot could help Immune-Compromised patients fight infections
Disease control OngoingThis phase 3 trial is testing a new medicine called Newnorm, a concentrated antibody solution given as a shot under the skin, in 50 people with primary immunodeficiency (a condition where the immune system doesn't work properly). The goal is to see if Newnorm can prevent serious …
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for older leukemia patients: targeted combo shows promise
Disease control OngoingThis study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission.…
Phase: PHASE2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy shows promise for older AML patients
Disease control OngoingThis study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by mai…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for Hard-to-Treat myeloma: cevostamab trial underway
Disease control OngoingThis study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how sa…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy drug tested for rare blood cancers
Disease control TerminatedThis study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Walking workouts may sharpen the MS brain — a trial puts it to the test
Disease control OngoingThis trial tests whether a 12-month aerobic walking program can improve cognitive processing speed and brain connectivity in adults with multiple sclerosis who have slowed thinking. Participants will be randomly assigned to one of two home-based walking programs that differ in in…
Phase: PHASE1 • Sponsor: Kessler Foundation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New ocrelizumab formula under study for MS patients
Disease control OngoingThis study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new injection calm psoriatic arthritis?
Disease control OngoingThis trial tests whether an investigational drug called SHR-1314 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. Participants receive either SHR-1314 or a placebo injection over 24 weeks, with follow-up for safety. The study aims to s…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug cocktail aims to wipe out hidden myeloma cells after transplant
Disease control OngoingThis phase 2 trial tests whether combining belantamab mafodotin (a targeted antibody-drug conjugate) with lenalidomide can eliminate minimal residual disease in multiple myeloma patients who still have detectable cancer after a stem cell transplant. The study enrolls 4 adults who…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for incurable blood cancer
Disease control OngoingThis study tests whether combining two drugs, epcoritamab and lenalidomide, can shrink or eliminate tumors in people with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. About 29 adults with stage 1-3a disease who need treatment will rece…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Stem cell transplant or drug combo: which better prevents leukemia return in seniors?
Disease control TerminatedThis study tests two strategies to keep acute myeloid leukemia (AML) from coming back in people aged 65 and older who have achieved remission after initial treatment. One group receives a stem cell transplant, while the other continues on a maintenance drug combination of azaciti…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: drug duo aims to shrink tumors and delay progression
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control TerminatedThis early-stage trial tests a new treatment called P-CD19CD20-ALLO1, a type of CAR-T cell therapy, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 162 participants and aims to check if the therapy is safe and tolerable. It also l…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill shows promise for Tough-to-Treat leukemias
Disease control OngoingThis study tests an oral drug called ONC201 in people whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or not responded to standard treatments. The trial has two phases: Phase I finds the safest dose, and Phase II checks if the drug shrinks or control…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a weekend steroid pill stop vitiligo spreading in kids?
Disease control OngoingThis study tests whether taking dexamethasone pills twice a week for 3 months can stop active vitiligo from spreading in children aged 4 to 9. Researchers will also monitor side effects, especially on growth and bone health. The goal is to control the disease, not cure it.
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Supercharged immune cells take aim at myeloma
Disease control OngoingThis early-stage trial tests whether specially trained immune cells can safely target and attack multiple myeloma, as well as its early forms MGUS and smoldering myeloma. Up to 36 participants will receive two infusions of their own T cells that have been engineered to recognize …
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Engineered t cells take on tough leukemia in early trial
Disease control OngoingThis early-stage study tests a new cell therapy for adults with a hard-to-treat type of leukemia (ALL). Doctors take a patient's own white blood cells, add a special gene to help them find and kill cancer cells, and give them back after chemotherapy. The main goals are to check s…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New antibody treatment aims to keep myeloma in check after transplant
Disease control OngoingThis phase 2 trial tests whether daratumumab, an antibody that targets cancer cells, can improve outcomes for people with multiple myeloma after they receive a stem cell transplant. The study involves 31 participants and is currently active but not recruiting. The main goal is to…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
MS treatment showdown: does starting strong early prevent disability?
Disease control OngoingThis trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a CBD cream soothe Eczema's relentless itch?
Disease control ENROLLING_BY_INVITATIONThis phase 2 trial is testing whether a 5% cannabidiol (CBD) cream can reduce itching and skin severity in adults with chronic eczema conditions like atopic dermatitis and nummular eczema. About 60 participants will apply the CBD cream or a standard steroid cream for 4 weeks. The…
Phase: PHASE2 • Sponsor: Khon Kaen University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug may extend remission after CAR-T in myeloma
Disease control TerminatedThis phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New targeted therapy challenges standard chemo for younger CLL patients
Disease control OngoingThis study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody drug shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows promise against blood cancer
Disease control OngoingThis study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to stop aggressive lymphoma in its tracks
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for lymphoma patients: drug combo aims to keep cancer at bay longer
Disease control OngoingThis study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug shows promise for Crohn's sufferers in Mid-Stage trial
Disease control OngoingThis study tests a new drug called AZD7798 in 120 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and improve the appearance of the gut lining. Participants are randomly assigned to receive either the drug or a placebo, and neither the…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Head-to-Head: which drug tames ulcerative colitis better?
Disease control OngoingThis study compares two approved drugs, risankizumab and vedolizumab, in about 530 adults with moderate to severe ulcerative colitis who have not tried targeted therapies before. Participants will receive one of the two drugs for about a year. The main goal is to see which drug b…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Triple threat: new drug combo aims to beat CLL in younger patients
Disease control OngoingThis phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Which psoriasis cream causes less skin discoloration? new study aims to find out
Disease control ENROLLING_BY_INVITATIONThis study compares two standard psoriasis creams—a steroid and a newer drug called tapinarof—to see which one causes less skin color change after treatment. Forty adults with darker skin types will use one cream daily on their legs for up to 12 weeks. Researchers will track pigm…
Phase: PHASE2, PHASE3 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New triple therapy could let some CLL patients stop treatment
Disease control OngoingThis phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New study tracks Acalabrutinib's Real-World success in CLL patients
Disease control OngoingThis study follows 192 people with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug for at least 24 months and how it works in different groups, like those new to treatment …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immunotherapy drug blinatumomab aims to boost leukemia survival in major trial
Disease control OngoingThis Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a drug delay cancer in High-Risk patients?
Disease control OngoingThis study compares the drug lenalidomide to simply watching and waiting in people with high-risk smoldering multiple myeloma, a condition that may turn into active cancer. The goal is to see if lenalidomide can delay progression and improve outcomes. About 226 participants were …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New shot shows promise against tough lymphoma in japanese study
Disease control OngoingThis trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control OngoingThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New antibody cocktail aims to tame ulcerative colitis for good
Disease control ENROLLING_BY_INVITATIONThis study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …
Phase: PHASE2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is …
Phase: PHASE2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New study puts omnipod 5 to the test in Real-World diabetes management
Disease control OngoingThis study is testing the Omnipod 5, a tubeless insulin pump that automatically adjusts insulin delivery, in real-world settings for people with type 1 diabetes. About 304 participants aged 2 and older will use the system for the first time. Researchers will track blood sugar con…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThis study tests whether guselkumab, given as a shot under the skin, can help people with moderate to severe Crohn's disease achieve remission and heal their gut lining. About 350 adults who have not responded well to other treatments will receive either guselkumab or a placebo. …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could CAR t cells tame autoimmune brain diseases?
Disease control OngoingThis early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThis large study tests whether guselkumab, an injected drug, can control symptoms and heal the gut lining in people with moderate to severe Crohn's disease. About 1,400 participants will receive guselkumab, an existing treatment (ustekinumab), or a placebo. The goal is to see if …
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase: PHASE2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase: PHASE4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells aim to tame lupus without daily pills
Disease control OngoingThis phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with severe colitis: oral drug shows promise
Disease control OngoingThis study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug reduce bloodletting for polycythemia vera?
Disease control TerminatedThis trial investigates whether ropeginterferon alfa-2b can help people with polycythemia vera, a condition where the body makes too many red blood cells. The study will compare the drug to standard care, which includes phlebotomy (removing blood) and aspirin. About 70 adults wit…
Phase: PHASE4 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug safely control eczema over the long haul?
Disease control ENROLLING_BY_INVITATIONThis trial is investigating whether long-term use of an experimental drug called IMG-007 can safely control moderate-to-severe eczema (atopic dermatitis). The study enrolls people who have already completed a previous IMG-007 trial and will receive the drug as a shot under the sk…
Phase: PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
Disease control OngoingThis phase 4 trial tests whether adding pioglitazone to an SGLT2 inhibitor (dapagliflozin) and insulin can lower blood sugar more effectively in people with type 1 diabetes while preventing a rise in ketones, which can lead to a dangerous condition called ketoacidosis. About 120 …
Phase: PHASE4 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a personalized drug strategy wipe out hidden myeloma cells?
Disease control OngoingThis phase 2 trial tests whether a combination of daratumumab, lenalidomide, and dexamethasone, followed by a stronger regimen if needed, can make multiple myeloma undetectable at a deep level (MRD-negative) in newly diagnosed patients. The treatment plan adapts based on each per…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a PET-MRI tracer reveal where CAR-T cells go in myeloma?
Disease control OngoingThis phase 1 trial tests whether a special imaging tracer can track CAR-T cells in people with extramedullary myeloma, a type of myeloma that forms tumors outside the bone marrow. Participants receive cilta-cel, a CAR-T therapy targeting the BCMA protein on myeloma cells, along w…
Phase: PHASE1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new drug calm the immune System's attack on blood cells?
Disease control OngoingThis study is testing an experimental drug called povetacicept in adults with autoimmune cytopenias — conditions where the immune system mistakenly destroys blood cells, leading to low platelet counts (immune thrombocytopenia) or anemia (autoimmune hemolytic anemia and cold agglu…
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can stem cells harvested during surgery heal Crohn's fistulas?
Disease control TerminatedThis trial explores whether stem cells taken from a patient's own bone marrow during surgery can help treat fistulas—abnormal tunnels under the skin—caused by Crohn's disease. The stem cells are prepared quickly in the operating room and injected into the fistula tract. Researche…
Phase: NA • Sponsor: Oxford University Hospitals NHS Trust • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?
Disease control OngoingThis study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…
Phase: PHASE2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug tame vasculitis with fewer side effects?
Disease control OngoingThis study tracks the safety of avacopan, a medication for ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. Researchers will compare side effects like liver injury, heart problems, serious infections, and cancer in people taking avacopan ve…
Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
Disease control OngoingThis study tests whether a six-month course of dupilumab can calm the immune system enough for patients with severe olive pollen asthma to then benefit from standard allergy immunotherapy. Researchers will use advanced molecular profiling to understand how the treatment restores …
Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a cancer drug reboot the immune system after a stem cell transplant?
Disease control OngoingThis phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…
Phase: PHASE2 • Sponsor: Divaya Bhutani • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a targeted drug boost standard therapy for a rare lymphoma?
Disease control OngoingThis phase 3 trial is testing whether adding the targeted drug ibrutinib to standard rituximab therapy can improve outcomes for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants are randomly assigned to receive either ibrutinib plus rituximab…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a biologic drug outperform standard therapy for a rare blood cancer?
Disease control OngoingThis phase 3 trial compares the biologic drug P1101 (ropeginterferon alfa-2b) against the standard drug anagrelide in people with essential thrombocythemia, a rare blood cancer that causes too many platelets. The study enrolls adults who have not responded well to the first-line …
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a targeted drug boost standard chemo for a rare blood cancer?
Disease control OngoingThis trial tests whether adding acalabrutinib—a targeted drug that blocks a key enzyme in cancer cells—to a standard chemotherapy cocktail (modified VR-CAP) can improve outcomes for people with mantle cell lymphoma who are eligible for a stem cell transplant. The study enrolls ad…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
Disease control OngoingThis phase 2 trial is testing whether adding the antibody rituximab to either pentostatin or bendamustine can improve outcomes for people with hairy cell leukemia that has relapsed or not responded to standard treatments. Participants are randomly assigned to one of the two drug …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New pill targets genetic weakness in Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Digital dashboard aims to transform diabetes care for kids
Disease control ENROLLING_BY_INVITATIONThis study tests whether a digital platform called Haibu Diabetes helps children with type 1 diabetes manage their condition better. The platform collects health data from devices and shares it with patients, caregivers, and doctors through a single dashboard. Researchers will co…
Phase: NA • Sponsor: University of British Columbia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Three telehealth sessions could ease the burden of type 1 diabetes on families
Disease control OngoingThis trial tests a brief, three-session telehealth program called the T1D Parent Check-In for parents of children (ages 8–17) newly diagnosed with type 1 diabetes. The program aims to help parents feel more confident, reduce family conflict, and improve the child's quality of lif…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control ENROLLING_BY_INVITATIONThis study investigates whether tirzepatide, a drug used for diabetes and weight loss, can reverse biological aging in people with HIV who are virally suppressed and have obesity. Participants receive tirzepatide for 25 weeks after a diet program. Researchers measure epigenetic a…
Phase: PHASE4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can pressurized oxygen boost cord blood transplants?
Disease control OngoingThis study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug D-2570 aims to quiet Flare-Ups in ulcerative colitis
Disease control OngoingThis study tests whether an experimental drug called D-2570 can help people with moderately to severely active ulcerative colitis achieve remission. About 120 adults will receive either D-2570 or a placebo daily for 12 weeks. The main goal is to see if more people on D-2570 reach…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Triple-Drug attack aims to outsmart mantle cell lymphoma
Disease control OngoingThis phase II trial tests a combination of three targeted drugs—acalabrutinib, umbralisib, and ublituximab—in people with previously untreated mantle cell lymphoma. The drugs work by blocking signals that help cancer cells grow and by helping the immune system attack them. The st…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could your own gut bacteria restore bowel control after cancer surgery?
Disease control OngoingThis study tests whether transplanting a person's own fecal bacteria into the bowel before ileostomy reversal can improve bowel and anal function after rectal cancer surgery. Participants receive four weekly enemas made from their own stool. The goal is to reduce symptoms like le…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New HIV drug candidate targets resistant strains
Disease control OngoingThis study tests a new drug called ACC017 in adults with HIV that has become resistant to standard treatments. The trial aims to see if ACC017 can lower the amount of virus in the blood to undetectable levels. Participants receive either ACC017 or a placebo for two weeks, followe…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug aims to stop blood cancer return after transplant
Disease control OngoingThis phase 1 trial tests whether the drug tagraxofusp can help prevent relapse in people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, or chronic myelomonocytic leukemia) who have recently received a stem cell transplant. Participant…
Phase: PHASE1 • Sponsor: Karen Ballen, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Nerve-Zapping showdown: which procedure best stops a runny nose?
Disease control ENROLLING_BY_INVITATIONThis trial compares three FDA-cleared in-office procedures that treat chronic non-allergic rhinitis by targeting the posterior nasal nerve. Radiofrequency ablation (using RhinAer or Neuromark) uses heat, while cryoablation (ClariFix) uses extreme cold to reduce nerve signals that…
Phase: NA • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma
Disease control OngoingThis study looks at how well the drug tafasitamab works in adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. Researchers will collect real-world data from 50 patients who are not eligible for a stem cell transplant. The m…
Sponsor: TTY Biopharm • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene therapy offers hope for 'Bubble Boy' disease without a donor
Disease control TerminatedThis trial tests a gene therapy for infants under 2 years old with RAG1-deficient severe combined immunodeficiency (SCID), a life-threatening condition where the immune system barely works. The therapy uses the child's own blood stem cells, modified with a corrected gene, to try …
Phase: PHASE1, PHASE2 • Sponsor: Videja B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hip replacement liners put to the test in global study
Disease control OngoingThis study follows 300 people who receive a hip replacement using either the Vivacit-E or Longevity liner, both made of a special plastic designed to last longer. The goal is to see how well these liners hold up over time, measuring how many are still in place without needing rep…
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to improve multiple myeloma treatment before and after stem cell transplant
Disease control OngoingThis phase 2 trial tests whether adding the drug daratumumab to a standard chemotherapy combination (bortezomib, cyclophosphamide, and dexamethasone) works better than the current standard (bortezomib, thalidomide, and dexamethasone) for newly diagnosed multiple myeloma patients …
Phase: PHASE2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Targeted drug aims to clear hidden leukemia before transplant
Disease control OngoingThis study tests whether the targeted drug inotuzumab ozogamicin can eliminate minimal residual disease (MRD) in adults with B-cell acute lymphoblastic leukemia (ALL) before they receive a stem cell transplant. Participants have either Philadelphia chromosome-positive or -negativ…
Phase: PHASE2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThis phase 3 study tests whether the drug luspatercept can help people with myelofibrosis-related anemia become independent of red blood cell transfusions. Participants are adults with myelofibrosis who are already taking a JAK inhibitor and need regular transfusions. The study c…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Four-Drug cocktail aims to crush myeloma before transplant
Disease control OngoingThis phase 3 trial tests whether adding the targeted antibody isatuximab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can achieve deeper remissions in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Particip…
Phase: PHASE3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a new pill keep multiple myeloma in check after transplant?
Disease control OngoingThis phase 2 trial is testing the drug iberdomide (CC220) as a long-term maintenance therapy for people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if taking iberdomide continuously can improve the depth of response and he…
Phase: PHASE2 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Epigenetic drugs aim to stop cancer return after transplant in kids
Disease control OngoingThis trial tests whether adding two drugs—vorinostat and low-dose azacitidine—after a stem cell transplant can help prevent relapse in children with certain myeloid cancers. The study includes children aged 1 to 21 with acute myeloid leukemia or related conditions. Researchers ar…
Phase: PHASE1 • Sponsor: Johns Hopkins All Children's Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Injectable HIV treatment tested over five years in thousands of patients
Disease control OngoingThis study follows over 3,300 people with HIV in Spain who switched from daily oral medication to a long-acting injectable combination of cabotegravir and rilpivirine. Researchers track how well the injections control the virus, how long patients stay on treatment, and any side e…
Sponsor: FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Simple cord milking procedure could protect newborn brains after difficult births
Disease control OngoingThis trial tests whether a quick procedure called umbilical cord milking—pushing blood from the cord into the baby before clamping—can improve brain development in newborns who are limp or not breathing well at birth. The study follows over 3,400 infants from the earlier CORDMILK…
Phase: NA • Sponsor: Nemours Children's Clinic • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can early parent coaching help infants with rare genetic disorders thrive?
Disease control ENROLLING_BY_INVITATIONThis study tests a program called PIXI that coaches parents of infants diagnosed with rare neurogenetic disorders (such as Fragile X, Angelman, or Down syndrome) during the first year of life. The program combines education about the disorder, guided parent-child interaction acti…
Phase: NA • Sponsor: RTI International • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a cancer drug shrink recurrent brain tumors?
Disease control OngoingThis phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Lab-Grown stem cells could speed immune recovery in blood cancer transplants
Disease control OngoingThis phase 2 trial tests whether adding lab-grown umbilical cord blood cells (dilanubicel) to a standard cord blood transplant helps people with blood cancers like leukemia recover their blood and immune cells faster. Participants receive chemotherapy and radiation to prepare the…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
Disease control OngoingThis early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…
Phase: PHASE1 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at High-Risk multiple myeloma
Disease control OngoingThis phase 1 trial tests a new approach for people with high-risk multiple myeloma who are already responding to their first or second line of therapy. The study uses a patient's own immune cells, engineered to recognize and attack the cancer (CART-BCMA), sometimes combined with …
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo aims to outsmart recurring lymphoma
Disease control OngoingThis phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug duo aims to tackle rare leukemia
Disease control ENROLLING_BY_INVITATIONThis phase 2 trial is testing a combination of two drugs, rituximab and zanubrutinib, in people with hairy cell leukemia or its variant. The goal is to see if this treatment can shrink or eliminate the cancer. Participants take zanubrutinib pills daily and receive rituximab infus…
Phase: PHASE2 • Sponsor: Bnai Zion Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
Disease control OngoingThis trial tests leflunomide, a drug used for rheumatoid arthritis, in people with chronic graft-versus-host disease (cGVHD) who depend on steroids. cGVHD is a complication of bone marrow transplant where donor immune cells attack the recipient's body. The goal is to see if leflu…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a 4-Minute chat rival a Dietitian's hour for heart health?
Disease control OngoingThis study tests whether a short, standardized 4-minute heart-healthy talk is as effective as a full 60-minute personalized session with a dietitian for lowering LDL cholesterol and improving diet. Participants are adults aged 30–80 with rheumatoid arthritis, psoriatic arthritis,…
Phase: NA • Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a Once-Daily steroid pill improve blood sugar control in Dual-Disease patients?
Disease control TerminatedThis trial tests whether taking hydrocortisone once a day (as a dual-release pill) leads to more stable blood sugar levels compared to the standard three-times-a-day regimen in adults who have both insulin-treated diabetes and Addison's disease. Participants will try both schedul…
Phase: NA • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Cheap drug combo may tame tough anemia
Disease control TerminatedThis trial tests a combination of two drugs, sirolimus and all-trans retinoic acid (ATRA), for people with autoimmune anemia that has not responded to standard treatments. Autoimmune anemia occurs when the immune system attacks red blood cells, causing fatigue and other symptoms.…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a maintenance drug keep myeloma at bay?
Disease control OngoingThis phase 2 trial tests whether the drug lenalidomide, taken as maintenance therapy, can delay the return of multiple myeloma in patients who have already responded to initial treatment. Participants take lenalidomide daily and are monitored for how long they remain free of dise…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New oral drug targets Tough-to-Treat leukemia
Disease control TerminatedThis early-stage trial tests an experimental oral drug called GB3226 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug works by blocking two pathways that help leukemia cells grow. The study aims to find a safe dose and check f…
Phase: PHASE1 • Sponsor: Galecto Biotech AB • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Ear stimulation may help repair nerve damage in multiple sclerosis
Disease control ENROLLING_BY_INVITATIONThis study tests whether stimulating the vagus nerve through the ear, while doing a hand coordination task, can improve motor function in people with multiple sclerosis. Participants will receive either active or sham stimulation during 30-minute sessions over a month, with follo…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to improve remission in older leukemia patients
Disease control OngoingThis phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxoli…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Drug combo aims to boost remission in rare lymphoma
Disease control OngoingThis phase 2 trial investigates whether combining rituximab (an antibody therapy) with venetoclax (a targeted pill) can effectively treat marginal zone lymphoma in people who have not yet received any treatment for their cancer. The study enrolls adults with measurable disease an…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Radioactive antibody hones in on cancer cells to boost transplant success
Disease control OngoingThis trial tests whether adding a radioactive antibody (90Y-DOTA-anti-CD25 basiliximab) to standard chemotherapy and targeted radiation can better prepare the bone marrow for a stem cell transplant in people with high-risk acute leukemia or myelodysplastic syndrome. The antibody …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
Disease control OngoingThis phase 1 trial tests a new approach for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The study uses two different CAR T cell therapies—one targeting a protein called GPRC5D and another targeting BCMA—given together …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Four-Drug cocktail aims to halt smoldering myeloma before it strikes
Disease control OngoingThis phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…
Phase: PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase: PHASE1, PHASE2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for myeloma patients with kidney failure: targeted drug tested in dialysis patients
Disease control OngoingThis study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Precision radiation may boost stem cell transplant success in tough leukemias
Disease control OngoingThis study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at tough childhood leukemia
Disease control OngoingThis trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could changing carbs and adding fiber improve blood sugar in type 1 diabetes?
Disease control OngoingThis study explores how different amounts of carbohydrates and a fiber supplement called inulin-FOS affect blood sugar control in adults with type 1 diabetes. Participants will try three two-week diets: one with 30% carbs, one with 50-55% carbs, and one with 50-55% carbs plus inu…
Phase: NA • Sponsor: Hacettepe University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for rare fever disorder: drug targets stubborn cases
Disease control TerminatedThis study tests whether anakinra (Kineret), a daily injection, can reduce monthly attacks in Chinese patients with Familial Mediterranean Fever (FMF) who do not respond to standard colchicine treatment. Three patients aged 2 years and older will receive anakinra for 6 months, wi…
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Childhood leukaemia trial seeks best chemo cocktail
Disease control OngoingThis trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Leukemia trial pulled before it started: safer transplant prep remains untested
Disease control TerminatedThis trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…
Phase: PHASE1, PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingThis phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …
Phase: PHASE3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug candidate targets Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Triple-Drug attack aims to wipe out mantle cell lymphoma
Disease control OngoingThis phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzum…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New endoscopic procedure aims to help people with obesity lose weight
Disease control OngoingThis study tests a new procedure called BEAM (Bariatric Endoscopic Antral Myotomy) to help people with obesity lose weight. The procedure uses a tube down the throat to make small cuts in the stomach muscle, aiming to change how the stomach empties. Twenty adults with a BMI betwe…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy targets autoimmune diseases, but trial never started
Disease control TerminatedThis study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Stem cells could offer new hope for severe eczema sufferers
Disease control OngoingThis Phase 2 trial tests whether a stem cell therapy called ADSTEM can safely and effectively treat moderate-to-severe atopic dermatitis (eczema). About 118 adults with long-lasting eczema that hasn't responded well to standard creams will receive either ADSTEM stem cells or a pl…
Phase: PHASE2 • Sponsor: EHL Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for older lymphoma patients: gentler drug combo shows promise
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients who have not yet been treated for mantle cell lymphoma. The goal is to see how well the drugs shrink or control the cancer. The study involves 48 participants aged …
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Diabetes drug shows promise for rare immune disorder
Disease control TerminatedThis phase 2 trial tests whether empagliflozin, a diabetes drug also known as Jardiance, can help people with glycogen storage disease type Ib (GSD-1b). GSD-1b causes low neutrophil counts, leading to frequent infections and bowel inflammation. The study gives empagliflozin orall…
Phase: PHASE2 • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New transplant method aims to reduce complications in bone marrow failure patients
Disease control OngoingThis study tests a stem cell transplant method for people with acquired or inherited bone marrow failure. Donor stem cells are specially processed to remove certain immune cells, which may lower the risk of graft rejection and graft-versus-host disease. The goal is to see if this…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stem cell transplant approach aims to tame deadly bone marrow cancer
Disease control OngoingThis early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bo…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Boosting CAR t cells: could a pill make lymphoma therapy more effective?
Disease control OngoingThis trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tame type 1 diabetes
Disease control OngoingThis study is testing whether a combination of two drugs, sotagliflozin and volagidemab, can improve blood sugar control in adults with type 1 diabetes. The 24 participants will receive both drugs or a placebo in a crossover design. The goal is to see if this approach can help ma…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising CAR-T trial for kids with rare vasculitis pulled before start
Disease control TerminatedThis trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for ch…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to improve leukemia treatment in young adults
Disease control ENROLLING_BY_INVITATIONThis clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost survival in aggressive leukemia
Disease control ENROLLING_BY_INVITATIONThis study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a monthly infusion tame stubborn IBD? new study tests faster dosing
Disease control OngoingThis study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo shows promise for older myeloma patients
Disease control OngoingThis study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants wil…
Phase: PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThis phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…
Phase: PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for myeloma: targeted drug combo shows promise in Late-Stage trial
Disease control OngoingThis phase 3 study tests whether adding the targeted drug belantamab mafodotin to standard medications (pomalidomide and dexamethasone) works better than another standard combo for people with multiple myeloma that has come back or stopped responding to treatment. About 302 parti…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New injectable methotrexate aims to tame rheumatoid arthritis with fewer side effects
Disease control OngoingThis phase 2 trial tests an injectable form of methotrexate called FBL-MTX for people with moderate-to-severe rheumatoid arthritis. The drug is designed to deliver methotrexate directly into the body using tiny fat bubbles, which may improve how well it works and reduce side effe…
Phase: PHASE2 • Sponsor: SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising combo targets tough blood cancer before transplant
Disease control OngoingThis phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The stud…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Texts and telehealth: new program aims to boost HIV med adherence in florida youth
Disease control OngoingThis study tests a program called Healthy Choices, which uses text messages and telehealth sessions to help young people with HIV (ages 18-29) in Florida manage their alcohol use and take their HIV medication every day. The goal is to improve daily medication adherence and viral …
Phase: NA • Sponsor: Florida State University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise against Hard-to-Treat blood cancers
Disease control OngoingThis study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can immune cells help islet transplants work better for diabetes?
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests whether adding immune cells—either the patient's own regulatory T cells or donor bone marrow cells—to a standard islet transplant can improve blood sugar control in people with brittle type 1 diabetes. About 24 adults aged 18 to 70 will receive one of…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
Disease control OngoingThis early-phase trial tests an investigational biologic called EA5 in adults with antiphospholipid syndrome (APS) who have had two or more blood clots despite standard blood-thinning therapy. The study enrolls about 12 participants and gives EA5 by intravenous infusion followed …
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a platelet-boosting drug improve blood counts in certain blood cancers?
Disease control TerminatedThis phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…
Phase: PHASE2 • Sponsor: Abhay Singh, MD MPH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control OngoingThis study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
A Super-Microscope could spot acid reflux in Kids—Without guesswork?
Diagnosis TerminatedThis study explores whether a very high-powered microscope can help diagnose acid reflux disease (GERD) in children by examining tiny gaps between cells in the esophagus. Researchers will compare biopsy samples from children with GERD, those with a related condition called eosino…
Sponsor: Baylor College of Medicine • Aim: Diagnosis
Last updated Aug 18, 2026 01:00 UTC
-
Blood test may predict rapid kidney decline in diabetes
Diagnosis OngoingThis trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this …
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a Light-Based device spot dangerous infection risk without a blood draw?
Diagnosis OngoingThis trial evaluates a new device called PointCheck that aims to detect severe neutropenia—a dangerous drop in infection-fighting white blood cells—without needing a blood sample. The study includes about 210 people with diffuse large B-cell lymphoma or multiple myeloma who are r…
Sponsor: Leuko Labs, Inc. • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Ultrasound, CT, and MRI put to the test for identifying childhood neck lumps
Diagnosis OngoingThis study investigates how well different imaging methods—ultrasound, CT, and MRI—can identify the cause of neck swellings in children. Researchers will compare imaging results with the final diagnosis from biopsy, lab tests, or follow-up. The goal is to see if imaging can relia…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Can a single platform predict your risk for multiple chronic diseases?
Diagnosis ENROLLING_BY_INVITATIONThis pilot study is testing whether the ADEN platform can accurately identify people at risk for heart disease, respiratory problems, cancer, autoimmune conditions, and frailty. Researchers will compare the platform's risk ratings to those made by doctors. If it works, the platfo…
Sponsor: Unidad de Investigación Genética Molecular • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
AI reads skin biopsies to spot hidden lymphomas
Diagnosis OngoingThis study is developing and testing an artificial intelligence model that analyzes images of skin biopsies to tell the difference between malignant lymphomas (like mycosis fungoides) and benign conditions that look similar. The AI will be trained on hundreds of archived slides a…
Sponsor: Cairo University • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Sound waves could reveal hidden fluid in swollen limbs
Diagnosis ENROLLING_BY_INVITATIONThis study tests a new ultrasound technique called SAVE that measures how stiff and fluid-filled arm tissues are in people with lymphedema. Researchers want to see if this method can accurately tell the difference between a swollen arm and a healthy one. If it works, it could hel…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New blood test screening targets hidden cancer in black communities
Diagnosis OngoingThis study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Can Youth-Led HIV testing programs last? new study aims to find out
Prevention OngoingThis study looks at how to keep a youth-friendly HIV self-testing program called 4YBY running in Nigeria. It will involve over 1,200 young people aged 14-24 who are at risk for HIV. Researchers will compare standard program delivery with an enhanced version that includes extra su…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
New program aims to cut heart risks in psoriasis patients
Prevention OngoingThis study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholest…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Smartphone app could help breast cancer survivors avoid painful arm swelling
Prevention OngoingThis study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…
Phase: NA • Sponsor: Inonu University • Aim: Prevention
Last updated Jul 16, 2026 00:00 UTC
-
New app aims to ease cancer symptoms for rural patients
Symptom relief TerminatedThis study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 01:00 UTC
-
New telehealth program aims to ease diabetes burden for rural families
Symptom relief OngoingThis study tests a program called REAL-Fam, designed to help families in rural areas manage a child's type 1 diabetes. About 16 families will either receive 12 telehealth sessions focused on diabetes routines and family participation, or just 3 basic check-in meetings. The goal i…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New cream could soothe eczema in babies as young as 3 months
Symptom relief OngoingThis study tests a cream called tapinarof on babies and toddlers aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, and the cream is compared to a placebo (inactive cream) for…
Phase: PHASE3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Healing from home: virtual reiki tested for lupus pain relief
Symptom relief OngoingThis pilot study will test whether virtual Reiki therapy can reduce pain and improve well-being in people with lupus. Twenty adults with lupus will receive 20-minute Reiki sessions once a week for 8 weeks, delivered remotely by a certified practitioner. Researchers will measure c…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New app aims to keep MS patients on their feet
Symptom relief OngoingThis study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New eczema drug shows promise in reducing itch and rash
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose,…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New program aims to help seniors master glucose monitors
Symptom relief OngoingThis study tests a remote education program called REST, designed to help adults aged 65 and older with insulin-treated diabetes start and keep using continuous glucose monitors (CGMs). The goal is to reduce dangerous low blood sugar episodes and improve overall glucose control. …
Phase: NA • Sponsor: Joslin Diabetes Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Online course aims to boost diet and Self-Care for MS and fatigue patients
Symptom relief OngoingThis study is testing whether an online course can help people with multiple sclerosis, long COVID, fibromyalgia, or cancer-related fatigue adopt healthier diets and self-care habits. Researchers will measure changes in quality of life, fatigue, and mental health. The goal is to …
Phase: NA • Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a robot help stroke survivors with HIV walk again?
Symptom relief OngoingThis trial explores whether an affordable robot can help people with HIV who have had a stroke improve their arm and leg function. Participants will use the robot for rehabilitation exercises, and researchers will measure changes in movement, balance, and quality of life. The goa…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Shock therapy for needle pain: TENS device tested on psoriasis patients
Symptom relief OngoingThis study tests whether a TENS (transcutaneous electrical nerve stimulation) device can reduce the pain of biologic injections in people with psoriasis. About 20 adults will receive their injection in one thigh without TENS and in the other thigh with TENS pads placed nearby. Th…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog
Symptom relief OngoingThis trial tests whether a small device that stimulates the vagus nerve through the ear can improve quality of life for people with long COVID who also meet the criteria for ME/CFS (chronic fatigue syndrome). Participants will use the device daily for six weeks, and researchers w…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
New robotic suit with electric zaps aims to restore walking after brain or spinal injury
Symptom relief OngoingThis study is testing a robotic lower-limb exoskeleton combined with functional electrical stimulation (FES) to help people with conditions like spinal cord injury, brain injury, or multiple sclerosis improve their walking. The device provides robotic support and electrical stimu…
Phase: NA • Sponsor: ABLE Human Motion S.L. • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Custom insoles may steady the steps of MS patients — a trial puts them to the test
Symptom relief OngoingThis trial tests whether custom-designed sensorimotor insoles, worn daily for six months, can improve balance and walking in people with multiple sclerosis. Fifty adults with MS (mild to moderate disability) will be randomly assigned to receive the insoles or continue their usual…
Phase: NA • Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can video coaching help ease arthritis symptoms?
Symptom relief OngoingThis study tests whether a home-based exercise program guided by online videos can improve symptoms and quality of life in people with axial spondyloarthritis, a type of arthritis affecting the spine. Participants follow video exercises for 3 months, and researchers compare their…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a simple body wash and cream soothe eczema without a prescription?
Symptom relief OngoingThis trial tests whether a daily routine using Rejuvaskin Eczema Body Wash followed by Skin Recovery Cream can improve dryness, roughness, itch, and irritation in adults with eczema-prone skin. Thirty-five participants aged 18 to 65 use the products once daily for 4 weeks and rep…
Phase: NA • Sponsor: Rejuvaskin • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Menthol gloves may offer quick itch relief for eczema sufferers
Symptom relief OngoingThis study tests whether wearing menthol-infused gloves and foot-covers for just five minutes a day can reduce itching in people with atopic dermatitis (eczema). Participants will use the gloves five days on, two days off for four weeks, then stop for two weeks of follow-up. The …
Phase: PHASE2 • Sponsor: Taiwan Municipal An-Nan Hospital-China Medical University • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Breathing technique may enhance lymphedema therapy in breast cancer survivors
Symptom relief OngoingThis study investigates whether adding diaphragmatic breathing exercises to standard manual lymphatic drainage (MLD) therapy reduces arm swelling and pain better than MLD alone in women who developed lymphedema after a radical mastectomy. Participants are female breast cancer sur…
Phase: NA • Sponsor: University of Lahore • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can an online program help health students beat stress?
Symptom relief OngoingThis study tests an 8-week online stress management program for health students in Sfax, Tunisia. The program combines cognitive-behavioral therapy and mindfulness meditation through videos, exercises, and motivational messages. Researchers will measure changes in stress, anxiety…
Phase: NA • Sponsor: University of Sfax • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Spinal zaps at home could restore hand control in MS
Symptom relief ENROLLING_BY_INVITATIONThis pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New app aims to ease depression and pain in ankylosing spondylitis patients
Symptom relief OngoingThis pilot study tests a WeChat-based program that provides daily mental health check-ins and tailored coping strategies for people with ankylosing spondylitis who also have mild-to-moderate depression or anxiety. Thirty-six adults will be split into two groups: one receives the …
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Peer support may help MS patients stay on track with meds
Symptom relief OngoingThis pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can online therapy help scleroderma patients manage daily life?
Symptom relief OngoingThis pilot study tests whether a personalized online occupational therapy program is feasible and helpful for adults with scleroderma. Twenty-four participants in Spain will either receive eight online therapy sessions over four weeks plus usual care, or usual care alone. The stu…
Phase: NA • Sponsor: Universidad de Zaragoza • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can talk therapy ease the mental burden of HIV? new study tests two approaches
Symptom relief OngoingThis study compares two types of talk therapy—Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT)—for HIV/AIDS patients experiencing psychological distress. 72 adults on antiretroviral therapy will receive 8 weekly sessions of either therapy or standard…
Phase: NA • Sponsor: Sadia Batool • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Do extra biopsies during colonoscopy help IBD patients? major study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether taking extra random biopsies during a colonoscopy helps find precancerous growths in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 1,600 participants will be randomly assigned to one of two biopsy…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused ENROLLING_BY_INVITATIONThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 01:00 UTC
-
New study aims to pinpoint fastest Crohn's symptom relief
Knowledge-focused OngoingThis study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better und…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Why are transplant survivors at higher heart risk? new study seeks answers
Knowledge-focused OngoingThis study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Digital tools aim to close learning gaps for young cancer survivors
Knowledge-focused OngoingThis study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Could muscle loss predict blood cancer outcomes?
Knowledge-focused OngoingThis study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a 7-Day genomic test improve lymphoma treatment?
Knowledge-focused OngoingThis study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can lifestyle choices after a stroke extend life and prevent a second one?
Knowledge-focused OngoingThis study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…
Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive study aims to uncover hidden triggers of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New screening study targets hidden diabetes and celiac disease in High-Risk communities
Knowledge-focused OngoingThis study is screening 115 underserved children and adults who are at risk for type 1 diabetes or celiac disease. Researchers will use blood tests to find early signs of these conditions, aiming to improve how we detect them. The goal is to catch these diseases sooner, especiall…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
MS drug levels in breast milk under study for nursing moms
Knowledge-focused OngoingThis study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Simple blood test may predict lymphoma treatment success
Knowledge-focused OngoingThis study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Are clinics missing advanced HIV cases? a new study investigates
Knowledge-focused TerminatedThis study looks at how often CD4 cell counts are measured when adults in Zambia begin or restart antiretroviral therapy (ART) after a long break. The goal is to see how many people have advanced HIV disease and whether low testing rates prevent proper care. Researchers will asse…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Heart scarring in HIV: researchers probe substance use link
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will use cardiac MRI to examine how stimulant and polysubstance use affects heart scarring and inflammation in 400 people with and without HIV. Participants will have one study visit for a detailed heart scan. The goal is to better understand the combined…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Ear zap for IBD? tiny study tests nerve stimulation for gut relief
Knowledge-focused ENROLLING_BY_INVITATIONThis pilot study tests whether daily, at-home stimulation of a nerve in the ear can change brain activity in people with inflammatory bowel disease (IBD) who are in remission. Fifteen adults with Crohn's disease or ulcerative colitis will use a small device for 28 days and underg…
Phase: EARLY_PHASE1 • Sponsor: University of Gdansk • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Dust mite asthma study aims to uncover how dupilumab works inside the body
Knowledge-focused OngoingThis study looks at how dupilumab changes the way the nose and blood respond to house dust mites in adults with allergic asthma. Participants will be exposed to dust mites in a special chamber and receive either dupilumab or a placebo. The goal is to understand the drug's effects…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
A simple hospital checklist could flag hidden malnutrition in kids with IBD
Knowledge-focused OngoingThis study tests whether a standard nutrition screening tool, called PYMS, can accurately identify children with Crohn's disease or ulcerative colitis who are at risk of malnutrition. Researchers will use the tool on 2,000 children aged 4–18 with IBD in outpatient and inpatient c…
Sponsor: University of Glasgow • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Brain shrinkage as a crystal ball for MS progression?
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study follows about 2,400 people with relapsing-remitting multiple sclerosis (MS) across Germany for up to six years. It asks whether loss of volume in the thalamus—a deep brain region—tracks with worsening disability, measured by the EDSS scale. Using standard…
Sponsor: Jung Diagnostics GmbH • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can Early-Life factors steer preterm and term infant health?
Knowledge-focused OngoingThis study follows mother-infant pairs from birth to 24 months to see how early nutrition, environmental exposures, and family factors relate to growth, development, and allergies in preterm and term infants. Researchers will use questionnaires and biological samples to examine h…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New tool aims to measure Kids' GVHD symptoms more accurately
Knowledge-focused OngoingThis study aims to create a symptom questionnaire specifically for children and teens living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Current symptom scales are designed for adults, but children may describe their symptoms differently. Research…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can we predict who will benefit from cladribine? new study aims to find out
Knowledge-focused OngoingThis observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New study aims to understand balance issues in brain diseases to improve rehab
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at balance and movement problems in people with stroke, Parkinson's disease, or multiple sclerosis. Researchers will use special devices to measure how well participants can keep their balance and walk. The goal is to learn more about these issues so that rehabil…
Phase: NA • Sponsor: Somogy Megyei Kaposi Mór Teaching Hospital • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Fatigue study seeks to unravel mystery of exhaustion
Knowledge-focused OngoingThis study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …
Sponsor: National Center for Complementary and Integrative Health (NCCIH) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New program aims to ease diabetes care transition for teens
Knowledge-focused OngoingThis study tests a program called SHIFT2 that helps teens and young adults with type 1 diabetes prepare for the switch from pediatric to adult medical care. Participants work with a transition coach and receive messages to encourage self-management. The goal is to see if this sup…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Heart safety check for new myelofibrosis drug in healthy volunteers
Knowledge-focused OngoingThis study evaluates whether a single dose of TQ05105, a JAK inhibitor being developed for myelofibrosis, affects the heart's electrical activity (QT interval) in healthy Chinese adults. Sixty participants receive TQ05105, placebo, and moxifloxacin (a positive control) in a cross…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can a biologic drug tame juvenile arthritis in kids?
Knowledge-focused TerminatedThis study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New brain scan may predict chemo brain in young leukemia patients
Knowledge-focused TerminatedThis study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Real-World dupixent: does it live up to the hype for eczema?
Knowledge-focused OngoingThis study follows about 955 people aged 12 and older who are starting treatment with Dupixent (dupilumab) for atopic dermatitis, commonly known as eczema. The goal is to see how the drug performs in everyday clinical practice, not just in controlled trials. Researchers will trac…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Nanochip could spot lymphoma relapse early
Knowledge-focused OngoingThis pilot study is testing a nanochip (ILN biochip) to see if it can monitor how well treatment is working and detect relapse in people with diffuse large B-cell lymphoma. About 73 patients will provide blood samples for the chip to analyze genetic markers. The goal is to find o…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
A 20-Minute walk: a new way to boost brain health in MS?
Knowledge-focused OngoingThis study explores whether a brief, moderate-intensity walk can alter brain function and blood flow in people with multiple sclerosis. Participants will undergo MRI scans before and after either treadmill or overground walking at a brisk pace. The goal is to see if even a single…
Phase: EARLY_PHASE1 • Sponsor: Kessler Foundation • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New testing method may guide targeted treatments for young leukemia patients
Knowledge-focused OngoingThis study looks at whether a special type of testing, called leukemia profiling, can help find personalized treatment options for children and young adults up to age 30 with recurrent, refractory, or high-risk leukemias. Researchers analyze the genetic changes in each patient's …
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Mayo clinic study to uncover how insulin deprivation affects muscle in type 1 diabetes
Knowledge-focused TerminatedThis study aims to understand how insulin deprivation and high blood sugar affect protein synthesis in muscles and blood of people with type 1 diabetes. Researchers will use muscle biopsies and special amino acid labels to track protein production. The study involves 70 participa…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New study to uncover sleep secrets in brain disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to build a research group of 100 people with neurological diseases like stroke, Parkinson's, epilepsy, or dementia. Researchers will use overnight sleep tests and questionnaires to measure sleep patterns, breathing, and heart rate during sleep. The goal is to bett…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
No new treatment, just Check-Ups: gene therapy patients monitored for 15 years
Knowledge-focused ENROLLING_BY_INVITATIONThis study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Could HIV and age weaken vaccine protection? study investigates
Knowledge-focused OngoingThis study looks at how HIV infection and aging impact the body's response to the Prevnar 13 vaccine, which protects against pneumococcal bacteria. Researchers will measure antibody levels in the lungs, nasal passages, and blood of participants aged 21-45 or 55-75, comparing thos…
Phase: EARLY_PHASE1 • Sponsor: VA Eastern Colorado Health Care System • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can we predict Crohn's damage before it happens? a Long-Term study aims to find out
Knowledge-focused OngoingThis study follows people newly diagnosed with Crohn's disease for up to five years to see how the condition damages the bowel over time. Researchers will use imaging scans and other tests to track disease progression and understand how different treatments affect long-term outco…
Phase: NA • Sponsor: GLSMED Learning Health S.A. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Can we predict psoriasis relapse after biologics? a new study digs into the clues.
Knowledge-focused OngoingThis study investigates why some people with plaque psoriasis experience a relapse after treatment with biologic drugs, while others do not. Researchers will compare patients who relapsed with those who did not, looking at factors like age, lifestyle, lab results, and treatment h…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Could the key to better CAR-T therapy lie in the gut?
Knowledge-focused OngoingThis study explores whether the types of bacteria living in a person's gut can influence how well CAR-T cell therapy works for diffuse large B-cell lymphoma. Researchers will track changes in the gut microbiome of 69 patients from before treatment up to 18 months afterward. The g…
Sponsor: University of Bologna • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
AI may predict ulcerative colitis severity before a scope — a study puts it to the test
Knowledge-focused OngoingThis study is testing whether a machine learning model can predict the extent of ulcerative colitis (UC) in the colon using only symptoms, physical signs, and lab results — before a colonoscopy is done. Researchers will analyze data from 1,500 people with UC to build and validate…
Sponsor: Beijing University of Chinese Medicine • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Stool test may predict gut healing in ulcerative colitis
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a simple stool test can predict if the gut lining is healing in people with moderate-to-severe ulcerative colitis who are starting biologic therapy for the first time. Researchers will measure levels of a protein called calprotectin in stool samples …
Sponsor: Tang-Du Hospital • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
Knowledge-focused OngoingThis study aims to measure heart and metabolic risk markers—such as insulin resistance and fat distribution—in young adults aged 18 to 30 with type 1 diabetes and a body mass index under 25. Researchers will track changes over one year using glucose clamps and meal tests. The goa…
Phase: PHASE1 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Heartbeat clues may flag surgery risks in children
Knowledge-focused OngoingThis study looks at whether heart rate variability (small changes in heartbeat timing) and early signs of inflammation can help predict breathing or heart problems in children having their tonsils or adenoids removed. Researchers will monitor heart rhythms and measure immune mark…
Sponsor: Duzce University • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Blood test could end guesswork in rheumatoid arthritis treatment
Knowledge-focused OngoingThis study evaluates a blood test that uses genetic and epigenetic information to help doctors predict which rheumatoid arthritis medication will work best for each patient. Researchers will collect blood samples from 1,410 adults with rheumatoid arthritis who have not responded …
Sponsor: Aqtual, Inc. • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Scientists aim to create a universal rulebook for spotting aggressive MS lesions on MRI
Knowledge-focused OngoingThis study looks at how consistently doctors can identify paramagnetic rim lesions (PRLs) on MRI scans of people with multiple sclerosis. PRLs are a sign of more active and aggressive disease. By having experts from 15 centers review the same scans, the researchers aim to create …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Eye scans could spot Diabetes-Related vision damage years early
Knowledge-focused OngoingThis study uses a non-invasive eye scan called OCTA to examine tiny blood vessels in the retina of adults with type 1 diabetes. The goal is to detect early signs of diabetic retinopathy, a leading cause of vision loss, before symptoms appear. Researchers will measure vessel densi…
Sponsor: University of Athens • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
MS crystal ball: new biomarkers aim to predict disability before it strikes
Knowledge-focused OngoingThis study follows 300 people with multiple sclerosis to see whether advanced MRI scans, eye tests, and blood markers can better predict when disability will worsen. Current tools are not accurate enough to guide early treatment for each individual. The researchers will compare t…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Massive MS registry aims to decode why some patients worsen faster than others
Knowledge-focused OngoingThis observational study follows thousands of people with multiple sclerosis (MS) over many years to identify factors that predict how the disease will progress. Researchers collect detailed clinical data, MRI scans, and quality-of-life questionnaires from participants treated at…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Study aims to keep workers with chronic illnesses on the job
Knowledge-focused OngoingThis study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New brain scanner could reveal hidden effects of childhood neurological diseases
Knowledge-focused OngoingThis study uses a new, child-friendly brain imaging technique called OPM-MEG to understand how immune-related brain diseases (like autoimmune encephalitis and multiple sclerosis) and other brain conditions affect children aged 2 to 25. Standard scans often miss problems with memo…
Phase: NA • Sponsor: Aston University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Digital diary aims to decode painful flares in spine condition
Knowledge-focused OngoingThis study investigates how people with axial spondyloarthritis (axSpA) experience sudden worsening of symptoms, known as flares. Over 12 months, 40 participants use a digital diary to track symptoms, diet, lifestyle, and self-management strategies, and provide blood samples duri…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Eye tests could spot silent vision damage in lupus patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study investigates whether people with systemic lupus erythematosus (SLE) show early signs of retinal damage before they notice any vision problems. Researchers will use advanced eye imaging and vision tests to compare lupus patients with healthy volunteers. The goal is to f…
Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Simple squeeze exercise may ease arthritis pain, study hints
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a simple isometric (static) hand exercise can change how people with rheumatoid arthritis feel pain. Researchers will measure pain tolerance, pressure thresholds, and muscle oxygen levels in 66 adults. The goal is to see if this type of exercise can help …
Phase: NA • Sponsor: Zülal TATAR • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a more intense chemo regimen beat aggressive lymphoma?
Knowledge-focused OngoingThis study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Do vaccines still work during lymphoma treatment? new study aims to find out
Knowledge-focused OngoingThis study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Real-World study tracks elidel use in asian kids with eczema
Knowledge-focused OngoingThis study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment pe…
Sponsor: BGP Products Operations GmbH, a Viatris company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Simple blood test may spot hidden liver trouble in colitis patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…
Sponsor: University Hospital Dubrava • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy's long-term brain effects to be studied
Knowledge-focused TerminatedThis pilot study aimed to see if it is possible to use neuropsychological tests to measure thinking, memory, and emotional health in adults who received CAR-T therapy for aggressive lymphoma at least six months earlier. The study was withdrawn before enrolling any participants, s…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
HIV treatment showdown: could simpler drug regimens reduce inflammation?
Knowledge-focused OngoingThis study looks at HIV patients over 40 (or those on HIV therapy for over 10 years) who switched to either a three-drug or a two-drug antiretroviral regimen. Researchers will measure markers of inflammation in the blood and track how many patients develop other health conditions…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Do blood transfusions help at the end of life? a study asks patients and staff
Knowledge-focused OngoingThis study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New vitiligo registry aims to uncover disease trends in 2,500 patients
Knowledge-focused ENROLLING_BY_INVITATIONThis observational registry will follow 2,500 adults and adolescents with nonsegmental vitiligo to understand how the disease presents and progresses over time. Participants continue their usual care with a dermatologist. No experimental treatment is given; the goal is to collect…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists probe immune secrets of four skin diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused TerminatedThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Young adult leukemia study pulled before it began
Knowledge-focused TerminatedThis was a planned French study to collect information on chronic myeloid leukemia (CML) in young adults aged 18 to 30 who were treated with tyrosine kinase inhibitors. The goal was to describe their diagnosis, treatment choices, side effects, and quality of life. However, the st…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gene analysis may unlock secrets of bone marrow transplant complication
Knowledge-focused TerminatedThis study examines tissue samples from patients who developed graft-versus-host disease (GVHD) after a stem cell transplant. Researchers use a technology called nCounter to measure the activity of 800 immune-related genes in these samples. The goal is to identify a unique molecu…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for clues to predict blistering disease severity
Knowledge-focused OngoingThis study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to m…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Logbook study for stem cell patients pulled before start
Knowledge-focused TerminatedThis pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Hidden heart risk in kids with diabetes: new study investigates
Knowledge-focused OngoingThis study examines how common cardiac autonomic neuropathy (nerve damage affecting the heart) is in children and teens with type 1 diabetes. Researchers will monitor 75 participants using heart tests and check if longer diabetes duration or poor blood sugar control raises the ri…
Phase: NA • Sponsor: Marwa Abouelela Abd Elsalam • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC